Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss. And Novo Nordisk makes semaglutide, sold under the name Ozempic for diabetes and Wegovy for weight control. These drugs bring in billions of dollars annually for the pharma giants.So, it's no surprise that other companies are aiming to get in on this market where demand has been so high that, last year, it surpassed supply of existing drugs. And two names that have come up as potential players in the years to come are pharma powerhouse Pfizer (NYSE: PFE) and biotech Viking Therapeutics (NASDAQ: VKTX). Investors have waited eagerly for updates from each of their programs. And recently Pfizer's update wasn't a positive one. Now, my prediction is the pharma player's loss may be Viking's gain.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool